Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01755949 | Colchicine and CRP in Atrial Fibrillation and AF Ablation | PHASE2 | COMPLETED | 26 | — | — | Mar 1, 2013 | Dec 6, 2016 | May 9, 2019 | 1 | United States |
Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.
| Arm | Type | Description |
|---|---|---|
| Chronic atrial fibrillation, colchicine | ACTIVE_COMPARATOR | Colchicine 0.6 mg PO BID. Subjects not undergoing ablation. |
| Chronic atrial fibrillation, placebo | PLACEBO_COMPARATOR | Matching placebo. Subjects not undergoing ablation. |
| Pre-ablation, sinus rhythm, colchicine | ACTIVE_COMPARATOR | Colchicine 0.6 mg PO BID. Subjects undergoing ablation. |
| Pre-ablation, sinus rhythm, placebo | PLACEBO_COMPARATOR | Matching placebo. Subjects undergoing ablation. |
| Pre-ablation, AF, colchicine | ACTIVE_COMPARATOR | Colchicine 0.6 mg PO BID. Subjects undergoing ablation. |
| Pre-ablation, AF, placebo | PLACEBO_COMPARATOR | Matching placebo. Subjects undergoing ablation. |
| Name | Type | Description |
|---|---|---|
| Colchicine, 0.6 mg PO BID | DRUG | Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo |
| Matching placebo | DRUG | Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug |
Inclusion Criteria: * Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices. Diagnosis of AF will be made based on the 12 -lead surface ECG. * Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology laboratory for the procedure in sinus rhy...